Drugs / Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)
Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05375708 Background | Dec 2025 → Jun 2031 | colorectal cancer | UMC Utrecht | Suspended | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05375708 ↗ |